Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | METAP1 | P53582 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12505347 | 0.82 | NPC1 (0.57) | PTGS2PTGS1HTTPKMNPC1 | |
| SCHEMBL18158120 | 0.81 | PTGS2 (0.60) | PTGS2PTGS1HTTPKMNPC1 | |
| SCHEMBL305710 | 0.81 | PTGS2 (0.47) | PTGS2PTGS1HTTPKMNPC1 | |
| SCHEMBL787659 | 0.80 | KMT2A (0.55) | PTGS2HTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18157976 | 0.79 | PTGS1 (0.61) | PTGS2PTGS1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30430782 | 0.79 | PTGS2 (1.00) | PTGS2PTGS1HTTPKMNPC1 | |
| SCHEMBL7226092 | 0.79 | PTGS2 (1.00) | PTGS2PTGS1HTTPKMNPC1 | |
| SCHEMBL18157894 | 0.79 | PTGS2 (0.71) | PTGS2PTGS1HTTPKMNPC1 | |
| SCHEMBL17490970 | 0.78 | PTGS2 (0.60) | PTGS2PTGS1HTTPKMNPC1 | |
| 2-Picolinic Acid SCHEMBL28914674 | 0.78 | LMNA (0.77) | PTGS2PTGS1HTTPKMNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116212964-B | Iridium catalyst for hydrogen production from formic acid, and preparation method and application thereof | 中南大学 | 2024-09-10 | — | — | CN | claimed |
| CN-116212964-A | Iridium catalyst for hydrogen production from formic acid, and preparation method and application thereof | 中南大学 | 2023-06-06 | — | — | CN | claimed |
| US-20250206752-A1 | PI3K INHIBITORS | COGENT BIOSCIENCES, INC. | 2025-06-26 | — | — | US | disclosed |
| US-12281122-B1 | PI3K inhibitors | COGENT BIOSCIENCES, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2025029683-A1 | PI3K INHIBITORS | COGENT BIOSCIENCES, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| CN-116212964-B | Iridium catalyst for hydrogen production from formic acid, and preparation method and application thereof | 中南大学 | 2024-09-10 | — | — | CN | disclosed |
| CN-116212964-B | Iridium catalyst for hydrogen production from formic acid, and preparation method and application thereof | 中南大学 | 2024-09-10 | — | — | CN | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| CN-116212964-A | Iridium catalyst for hydrogen production from formic acid, and preparation method and application thereof | 中南大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-116212964-A | Iridium catalyst for hydrogen production from formic acid, and preparation method and application thereof | 中南大学 | 2023-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206752-A1 | PI3K INHIBITORS | PIK3CA, PIK3R5, PIK3R4 | PTGS2 3692/4885PTGS1 2493/4885HTT 1246/4885 |
| US-12281122-B1 | PI3K inhibitors | PIK3CA, PIK3R5, PIK3R4 | PTGS2 3692/4885PTGS1 2493/4885HTT 1246/4885 |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PTGS2 4015/4885PTGS1 3356/4885HTT 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.